4CPS-072 Real-world experience in haemophilia B patients after switching to fix extended half-life using pharmacokinetic population software and monocompartmental model
Background and ImportanceNew strategies have been developed for the prophylactic treatment of patients with haemophilia B (HB) such as extended half-life recombinant factor IX concentrates (rFIX EHL). These products have shown favourable pharmacokinetic properties, attaining a half-life 3- to 5-fold...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A47-A48 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Schreiben Sie den ersten Kommentar!